Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Turin – page 8

677 clinical trials in Turin, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Turin at a glance
677
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

677 trials in Turin

Open in trial search

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Glycogen storage disease type II

Recruiting

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Shionogi B.V.

Amyotrophic lateral sclerosis

Recruiting

A Study Testing the Safety of LTX-002 Sodium Given into the Spinal Canal in Adults with Amyotrophic Lateral Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LTX-002 SODIUM
  • Sponsor:Leal Therapeutics Inc.

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Neovascular age-related macular degeneration

Recruiting

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Follicle centre lymphoma follicular grade I, II - III

Recruiting

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Recruiting

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Acute myocardial infarction+1

Recruiting

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Humanitas Mirasole S.p.A.

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Turin

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and breast cancer treatments. Studies include evaluation of targeted therapies and immunotherapy approaches for various stages of disease.

  • Triple-negative breast cancer treatments
  • Advanced urothelial cancer therapy
  • Novel lymphoma interventions

Several trials are investigating combination therapies and maintenance treatments to improve patient outcomes.

02 Transplant Medicine

Research centered on improving outcomes in kidney transplantation, with particular focus on preventing delayed graft function and optimizing post-transplant care.

  • Graft function optimization
  • Novel immunosuppressive approaches
  • Post-transplant complications

Studies aim to enhance transplant success rates and reduce complications in organ recipients.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Crohn's Disease and pyoderma gangrenosum. Studies evaluate new biological therapies and combination treatments.

  • Inflammatory bowel disease management
  • Skin condition treatments
  • Novel therapeutic combinations

Focus on developing targeted treatments to improve disease control and patient quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.